title: Ebola haemorrhagic fever virus: pathogenesis, immune responses, potential prevention.
abstract: Ebola zoonotic RNA filovirus represents human most virulent and lethal pathogens, which induces acute hemorrhagic fever and death within few days in a range of 60-90% of symptomatic individuals. Last outbreak in 2014 in West Africa caused panic that Ebola epidemic can be spread to other continents. Number of deaths in late December reached almost 8,000 individuals out of more than 20,000 symptomatic patients. It seems that only a coordinated international response could counteract the further spread of Ebola. Major innate immunity mechanisms against Ebola are associated with the production of interferons, that are inhibited by viral proteins. Activation of host NK cells was recognized as a leading immune function responsible for recovery of infected people. Uncontrolled cell infection by Ebola leads to an impairment of immunity with cytokine storm, coagulopathy, systemic bleeding, multi-organ failure and death. Tested prevention strategies to induce antiviral immunity include: i. recombinant virus formulations (vaccines); ii. cocktail of monoclonal antibodies (serotherapy); iii. alternative RNA-interference-based antiviral methods. Maintaining the highest standards of aseptic and antiseptic precautions is equally important. Present brief review summarizes a current knowledge concerning pathogenesis of Ebola hemorrhagic disease and the virus interaction with the immune system and discusses recent advances in prevention of Ebola infection by vaccination and serotherapy.
authors.affiliation: Department Of Immunology, Jagiellonian University Medical College, Krakow, Poland. mmmarcin@cyf-kr.edu.pl.
authors.forename: Janusz
authors.initials: J
authors.lastname: Marcinkiewicz
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Bryniarski
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Nazimek
mesh_terms: D000354:Africa, Western / Q000453:epidemiology; D003140:Communicable Disease Control / Q000379:methods; D004196:Disease Outbreaks / Q000517:prevention & control*; D004197:Disease Reservoirs; D046129:Ebola Vaccines / Q000627:therapeutic use; D029043:Ebolavirus / Q000276:immunology / Q000302:isolation & purification / Q000472:pathogenicity*; D019142:Hemorrhagic Fever, Ebola / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission*; D006801:Humans
chemical_list: D046129:Ebola Vaccines
keywords: Ebola virus disease pathogenesis; immunity; vaccination